BlackBerry (NASDAQ:BBRY): Jefferies’ channel checks have indicated that global sales of the Z10 are slowing, while Q10 sales are doing better than expected. The firm still believes BlackBerry will beat consensus estimates for both the May and August quarters, and keeps a Buy rating on the stock with a $22 price target.
Broadcom (NASDAQ:BRCM): Macquarie has upgraded Broadcom to Outperform from Neutral, as the firm believes that the company is tracking above the mid-point of Q2 guidance due to better than expected wireless trends and an improving order outlook. Its price target has also been raised to $40.80, from $35.70.
JPMorgan (NYSE:JPM): Macquarie has transferred coverage on JPMorgan, with a Neutral rating down from an Outperform rating citing valuation and a lack of near-term catalysts for the downgrade. The price target is $57.
Clovis (NASDAQ:CLVS): JPMorgan has raised its price target on Clovis to $88 from $45, citing an increased probability of success for the company’s cancer drug CO-1686 following presentations at ASCO. The firm keeps an Overweight rating on the stock.